Jennifer Levin Carter MD, MPH, MBA Joins Transparency Life Sciences Advisory Board
TLS recently updated its Transparency Protocol Crowdsourcing© (TPC) technology that engages patients, physicians, and researchers to contribute to the setup and design of trials using a proprietary online survey tool. The results are then analyzed using AI-enabled natural language processing and TLS’ proprietary advanced analytic tools to help sponsors draft protocols more relevant to patient needs and clinical practice, which can help expedite both investigator and patient recruitment, result in fewer patients failing to complete a study and enhanced data quality. The technology, once implemented, can also help understand patient behavior utilizing historical data thereby enhancing engagement.
“Some of the key barriers to enrollment in clinical trials arise when patients are not engaged early enough in the design and implementation,” said Dr. Carter. “Right now, only three to seven percent of eligible patients enroll in clinical trials. This is often due to trial requirements such as the number of site visits. By collecting patient feedback on the design of trials in advance, TLS can help trial sponsors create more patient-centric clinical trials that can expedite enrollment, improve engagement and retention of patients, and hopefully, also, provide access to therapies in development for more diverse cohorts of patients.”
Dr. Carter has long been an entrepreneur and thought leader focused on improving patient access to emerging technologies. In 2018, she founded TrialzOWN, Inc., a healthcare company in stealth, and was CEO until its prelaunch acquisition by Integral Health in March 2019. Prior to TrialzOWN, Dr. Carter was the Founder and President of N-of-One®, Inc. She served as acting-CEO from 2008-2012, and Chief Medical Officer from 2012 until its acquisition by Qiagen (Market Cap $8B) in 2019. At N-of-One, Dr. Carter led the creation of award-winning solutions that delivered novel treatment strategies to hundreds of thousands of patients with cancer globally. She graduated Phi Beta Kappa, Summa Cum Laude with distinction with a BS in Molecular Biophysics and Biochemistry from Yale University, an MD from Harvard Medical School, an MPH from Harvard School of Public Health, and an MBA from the Sloan School at Massachusetts Institute of Technology.
“Jennifer brings a breadth of healthcare experience to our company. Her career efforts have focused on centering care around patients, finding ways that deliver new treatment options to more patients in a way that is also flexible and considerate of the patient’s lifestyle,” said Harry Glorikian, chief executive officer of Transparency Life Sciences. “Adding her to our advisory board will ensure we can provide customers with patient-centric solutions to maximize efficiencies for all parties involved.”
For more information on TLS and hybrid and virtual clinical trials, please visit www.transparencyls.com.
About Transparency Life Sciences
Transparency Life Sciences (TLS) is a leader in digital drug development services offering virtual and hybrid clinical trials. Rapid advances in digital technology and strong regulatory support create a historic opportunity for TLS to catalyze a fundamental transformation in clinical trial design and execution, significantly improving the quality of clinical trials while reducing their overall cost. TLS’s approach combines crowdsourcing and digital health technology to progress clinical trials with greater efficiency, patient engagement, and regulatory relevance. For more information, visit transparencyls.com/.
Managing Partner, Vuturo Group
Source: Transparency Life Sciences